# NIKA (Nika Pharmaceuticals, Inc.) - SEC EDGAR Financial Statements

> Nika Pharmaceuticals, Inc. reported $5.3K in total assets and a net loss of $83K through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/NIKA
- Markdown: https://convexityos.com/fundamentals/NIKA.md
- SEC CIK: 0001145604
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:38 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001145604&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$83K | Operating profit |
| Net Income | FY 2025 | -$83K | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.00 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $352 | Total debt: $349K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | $0 | $0 | $0 | $0 | -- |
| Total Operating Expenses | $76K | $96K | $65K | $3.18M | $15K | $8.9K |
| **Operating Income** | -$76K | -$96K | -$65K | -$3.18M | -$15K | -$8.9K |
| Income Before Tax | -$76K | -$96K | -$65K | -$3.18M | -$15K | -$8.9K |
| **Net Income** | -$76K | -$96K | -$65K | -$3.18M | -$15K | -$8.9K |
| Basic EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| **Diluted EPS** | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Basic Shares Outstanding | 1.05B | 1.02B | 876.1M | 724.0M | 396.1M | 13.2M |
| Diluted Shares Outstanding | 1.05B | 1.02B | 876.1M | 724.0M | 396.1M | 13.2M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Total Operating Expenses | $13K | $20K | $13K | $37K | $8.0K | $18K | $13K | $12K |
| **Operating Income** | -$13K | -$20K | -$13K | -$37K | -$8.0K | -$18K | -$13K | -$12K |
| Income Before Tax | -$13K | -$20K | -$13K | -$37K | -$8.0K | -$18K | -$13K | -$12K |
| **Net Income** | -$13K | -$20K | -$13K | -$37K | -$8.0K | -$18K | -$13K | -$12K |
| Basic EPS | $0.00 | $0.00 | $0.00 | -- | $0.00 | $0.00 | $0.00 | -- |
| **Diluted EPS** | $0.00 | $0.00 | $0.00 | -- | $0.00 | $0.00 | $0.00 | -- |
| Basic Shares Outstanding | 1.05B | 1.05B | 1.05B | -- | 1.04B | 1.03B | 1.03B | -- |
| Diluted Shares Outstanding | 1.05B | 1.05B | 1.05B | -- | 1.04B | 1.03B | 1.03B | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $1.9K | $2.1K | $20K | $864 | $399 | $1.6K |
| **Cash & Short-Term Investments** | $1.9K | $2.1K | $20K | $864 | $399 | $1.6K |
| **Total Current Assets** | $21K | $18K | $20K | $864 | $399 | $1.6K |
| **Total Non-Current Assets** | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Assets** | $21K | $18K | $20K | $864 | $399 | $1.6K |
| Short-Term Debt | $319K | $239K | $102K | $18K | -- | -- |
| **Total Current Liabilities** | $319K | $239K | $102K | $18K | $11K | -- |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $14K | -- |
| **Total Liabilities** | $319K | $239K | $102K | $18K | $24K | $11K |
| **Total Debt (incl. Leases)** | $319K | $239K | $102K | $18K | -- | -- |
| Common Stock | $105K | $102K | $88K | $88K | $40K | $13K |
| Retained Earnings | -$9.00M | -$8.93M | -$3.40M | -$3.34M | $152K | $137K |
| Accumulated Other Comp. Income | -- | -- | -- | -- | -- | $137K |
| **Total Stockholders' Equity** | -$298K | -$221K | -$82K | -$17K | -$24K | -$8.9K |
| Total Equity | -$298K | -$221K | -$82K | -$17K | -$24K | -$8.9K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $352 | $2.9K | $1.5K | $1.9K | $6.3K | $16K | $19K | $2.1K |
| **Cash & Short-Term Investments** | $352 | $2.9K | $1.5K | $1.9K | $6.3K | $16K | $19K | $2.1K |
| **Total Current Assets** | $5.3K | $9.9K | $21K | $21K | $24K | $32K | $35K | $18K |
| **Total Non-Current Assets** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Assets** | $5.3K | $9.9K | $21K | $21K | $24K | $32K | $35K | $18K |
| Short-Term Debt | $349K | $341K | $332K | $319K | $284K | $284K | $269K | $239K |
| **Total Current Liabilities** | $349K | $341K | $332K | $319K | $284K | $284K | $269K | $239K |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $349K | $341K | $332K | $319K | $284K | $284K | $269K | $239K |
| **Total Debt (incl. Leases)** | $349K | $341K | $332K | $319K | $284K | $284K | $269K | $239K |
| Common Stock | $105K | $105K | $105K | $105K | $104K | $103K | $103K | $102K |
| Retained Earnings | -$9.05M | -$9.04M | -$9.02M | -$9.00M | -$8.97M | -$8.96M | -$8.94M | -$8.93M |
| **Total Stockholders' Equity** | -$344K | -$331K | -$311K | -$298K | -$261K | -$253K | -$234K | -$221K |
| Total Equity | -$344K | -$331K | -$311K | -$298K | -$261K | -$253K | -$234K | -$221K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$76K | -$96K | -$65K | -$3.18M | $15K | -$8.9K |
| Change in Working Capital | -- | -- | -- | -- | -$10K | -- |
| **Operating Cash Flow** | -$80K | -$155K | -$65K | $34K | $15K | -$8.9K |
| Common Stock Issued | -- | -- | -- | $10K | -- | -- |
| **Financing Cash Flow** | $79K | $137K | $84K | $34K | $14K | $11K |
| **Net Change in Cash** | -$194 | -$18K | $19K | $465 | -$1.2K | $1.6K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$13K | -$20K | -$13K | -$37K | -$8.0K | -$18K | -$13K | -$12K |
| **Operating Cash Flow** | -$11K | -$7.6K | -$13K | -$39K | -$9.3K | -$19K | -$13K | -$28K |
| **Financing Cash Flow** | $8.4K | $9.0K | $13K | $34K | $0 | $15K | $30K | $29K |
| **Net Change in Cash** | -$2.6K | $1.4K | -$359 | -$4.4K | -$9.3K | $31K | -$17K | $697 |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Return on Assets (ROA) | -363.9% | -534.1% | -330.8% | -368485.5% | -3687.2% | -552.9% |
| Current Ratio | 0.07x | 0.07x | 0.19x | 0.05x | 0.04x | -- |
| Quick Ratio | 0.01x | 0.01x | 0.19x | 0.05x | 0.04x | -- |
| Operating Cash Flow Growth (YoY) | -- | -- | -292.3% | +129.2% | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Assets (ROA) | -1566.5% | -785.8% | -372.2% | -363.9% | -219.1% | -165.0% | -160.7% | -497.5% |
| Current Ratio | 0.02x | 0.03x | 0.06x | 0.07x | 0.08x | 0.11x | 0.13x | 0.07x |
| Quick Ratio | 0.00x | 0.01x | 0.00x | 0.01x | 0.02x | 0.05x | 0.07x | 0.01x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
